Suzy Jones has more than 35 years of biotech experience. Prior to founding DNA Ink 10 years ago, she headed the Business Development group at Genentech. Suzy spent the majority of her time in Business Development as the Head of Non-Oncology Licensing, responsible for overseeing Genentech licensing efforts in inflammation, infectious diseases, neurobiology, heme malignancies and enabling technologies. Suzy also managed BD for Genentech’s CD20 portfolio (Rituxan, Gazyva and Ocrevus). Her group executed numerous deals over a 10-year period. During her time in Genentech Business Development, the group was recognized in an IBM survey as the number one deal-making group in industry.
Prior to working in Business Development, Suzy conducted basic immunology research, and worked in product development where she managed several products at various stages of their life cycles, including Rituxan and Avastin, two of the first targeted therapies for cancer.
Suzy served as a member of the board a Calithera Biosciences (NASDAQ: CALA), Patrys (ASX: PAB), and is currently on the board of Red Bay Coffee – one of her social impact portfolio companies and a Bay Area B-Corp.
When she’s not working with clients, Suzy works as a social impact investor and advisor.
